SCP makes its first exit with Noden Pharma sale

• Noden focuses on the manufacturing of prescription medicines across a variety of cardiovascular treatments
• SCP bought Noden in July 2020
• The firm has exited the business having achieved a COC of 6.7x and an IRR of 151%

Stanley Capital Partners (SCP) announced that it has exited its portfolio company Noden Pharma. Dublin-headquartered Noden, which SCP invested in in July 2020, is a global speciality pharmaceutical company that is focused on the manufacturing of prescription medicines across a variety of cardiovascular treatments.

The buyer is a European business in the specialist pharmaceutical sector, SCP said.

SCP aided Noden’s inorganic and organic growth, the firm said. Noden also improved its operational efficiency, cashflow and secured an ongoing API source, securing a strong return for SCP and its investors in a short period of time, according to SCP. It is the firm’s first exit since it was founded in 2019 and resulted in a COC of 6.7x and an IRR of 151%.

“We used our research to both originate Noden and create value in the business, enabling them to transform the business from a subsidiary into a successful ongoing platform which resulted in a successful exit through our joint efforts in transforming the business,” said Simon Cottle, SCP founding partner.

SCP is a London-based European-focused mid-market private equity firm. It looks to invest in companies in the healthcare, technology and resource efficiency sectors. SCP targets businesses with enterprise values of $250 million to $2.5 billion.

The exit follows SCP’s purchase of French Pharma group Laboratoire XO earlier this month.